# SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT04146402** · PHASE3 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 330 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** SCT-I10A+chemo
- **DRUG:** Placebos+chemo

## Key facts

- **NCT ID:** NCT04146402
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-31
- **Primary completion:** 2022-01-29
- **Final completion:** 2022-07-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04146402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04146402, "SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04146402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*